- Home
- EXEL vs DAY Comparison
EXEL vs DAY Comparison
Compare EXEL & DAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXEL
- DAY
- Stock Information
- Founded
- EXEL 1994
- DAY 1992
- Country
- EXEL United States
- DAY United States
- Employees
- EXEL N/A
- DAY N/A
- Industry
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- DAY
- Sector
- EXEL Health Care
- DAY
- Exchange
- EXEL Nasdaq
- DAY NYSE
- Market Cap
- EXEL 9.8B
- DAY 9.1B
- IPO Year
- EXEL 2000
- DAY 2018
- Fundamental
- Price
- EXEL $43.04
- DAY $59.06
- Analyst Decision
- EXEL Buy
- DAY Buy
- Analyst Count
- EXEL 18
- DAY 13
- Target Price
- EXEL $38.76
- DAY $73.77
- AVG Volume (30 Days)
- EXEL 3.9M
- DAY 2.5M
- Earning Date
- EXEL 05-13-2025
- DAY 05-07-2025
- Dividend Yield
- EXEL N/A
- DAY N/A
- EPS Growth
- EXEL 237.58
- DAY N/A
- EPS
- EXEL 2.20
- DAY 0.16
- Revenue
- EXEL $2,298,922,000.00
- DAY $1,810,300,000.00
- Revenue This Year
- EXEL $10.39
- DAY $11.02
- Revenue Next Year
- EXEL $10.74
- DAY $11.87
- P/E Ratio
- EXEL $19.53
- DAY $364.70
- Revenue Growth
- EXEL 24.49
- DAY 14.97
- 52 Week Low
- EXEL $20.40
- DAY $47.08
- 52 Week High
- EXEL $48.85
- DAY $82.69
- Technical
- Relative Strength Index (RSI)
- EXEL 59.93
- DAY 53.99
- Support Level
- EXEL $42.21
- DAY $56.97
- Resistance Level
- EXEL $43.75
- DAY $58.74
- Average True Range (ATR)
- EXEL 1.60
- DAY 1.35
- MACD
- EXEL -0.09
- DAY -0.09
- Stochastic Oscillator
- EXEL 53.96
- DAY 73.56
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
About DAY DAYFORCE INC
Dayforce provides payroll and human capital management solutions targeting clients with 100-100,000 employees. Following the 2012 acquisition of Dayforce, Dayforce pivoted away from its legacy on-premises Bureau business to become a cloud HCM provider. As of fiscal 2022, about 80% of group revenue was derived from the flagship Dayforce platform geared toward enterprise clients. The remaining revenue is about evenly split between cloud platform Powerpay, targeting small businesses in Canada, and legacy Bureau products.